Cargando…

Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study

Background and Objectives: The treatment of Myeloma after the second relapse is still challenging. The aim of the study was to investigate the outcomes of the POM-DEX regimen in real clinical practice. Materials and Methods: We retrospectively and prospectively analyzed 121 patients with MM treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Giudice, Maria Livia, Gozzetti, Alessandro, Antonioli, Elisabetta, Orciuolo, Enrico, Ghio, Francesco, Ciofini, Sara, Candi, Veronica, Fontanelli, Giulia, Attucci, Irene, Formica, Giuseppe, Bocchia, Monica, Galimberti, Sara, Petrini, Mario, Buda, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466559/
https://www.ncbi.nlm.nih.gov/pubmed/34577823
http://dx.doi.org/10.3390/medicina57090900
_version_ 1784573172069171200
author Del Giudice, Maria Livia
Gozzetti, Alessandro
Antonioli, Elisabetta
Orciuolo, Enrico
Ghio, Francesco
Ciofini, Sara
Candi, Veronica
Fontanelli, Giulia
Attucci, Irene
Formica, Giuseppe
Bocchia, Monica
Galimberti, Sara
Petrini, Mario
Buda, Gabriele
author_facet Del Giudice, Maria Livia
Gozzetti, Alessandro
Antonioli, Elisabetta
Orciuolo, Enrico
Ghio, Francesco
Ciofini, Sara
Candi, Veronica
Fontanelli, Giulia
Attucci, Irene
Formica, Giuseppe
Bocchia, Monica
Galimberti, Sara
Petrini, Mario
Buda, Gabriele
author_sort Del Giudice, Maria Livia
collection PubMed
description Background and Objectives: The treatment of Myeloma after the second relapse is still challenging. The aim of the study was to investigate the outcomes of the POM-DEX regimen in real clinical practice. Materials and Methods: We retrospectively and prospectively analyzed 121 patients with MM treated with POM-DEX in three Italian sites in Tuscany. We assessed the efficacy based on IMWG Uniform Response Criteria in 106 patients who had received at least two courses of the POM-DEX regimen. The median time from diagnosis to use of POM-DEX was 65 months. POM-DEX median use was in the fourth-line therapy. 63.6% were exposed to lenalidomide or thalidomide, 40.5% to bortezomib or carfilzomib or ixazomib, 5.8% to mAbs in the immediately preceding line of therapy. Results: ORR was 43.4%. Median PFS and OS were 8.5 and 14 months. Eighty-nine patients received more than two courses: their median PFS and OS were 11 and 16 months. When used as the third line of therapy, median PFS and OS were 9 and 20 months and, when patients received POM-DEX for more than two courses, median PFS and OS were 14.5 and 22.5 months. Conclusions: POM-DEX is effective in RRMM, regardless of the latest exposure to IMiDs, PIs, and mAbs in the previous line of therapy.
format Online
Article
Text
id pubmed-8466559
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84665592021-09-27 Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study Del Giudice, Maria Livia Gozzetti, Alessandro Antonioli, Elisabetta Orciuolo, Enrico Ghio, Francesco Ciofini, Sara Candi, Veronica Fontanelli, Giulia Attucci, Irene Formica, Giuseppe Bocchia, Monica Galimberti, Sara Petrini, Mario Buda, Gabriele Medicina (Kaunas) Article Background and Objectives: The treatment of Myeloma after the second relapse is still challenging. The aim of the study was to investigate the outcomes of the POM-DEX regimen in real clinical practice. Materials and Methods: We retrospectively and prospectively analyzed 121 patients with MM treated with POM-DEX in three Italian sites in Tuscany. We assessed the efficacy based on IMWG Uniform Response Criteria in 106 patients who had received at least two courses of the POM-DEX regimen. The median time from diagnosis to use of POM-DEX was 65 months. POM-DEX median use was in the fourth-line therapy. 63.6% were exposed to lenalidomide or thalidomide, 40.5% to bortezomib or carfilzomib or ixazomib, 5.8% to mAbs in the immediately preceding line of therapy. Results: ORR was 43.4%. Median PFS and OS were 8.5 and 14 months. Eighty-nine patients received more than two courses: their median PFS and OS were 11 and 16 months. When used as the third line of therapy, median PFS and OS were 9 and 20 months and, when patients received POM-DEX for more than two courses, median PFS and OS were 14.5 and 22.5 months. Conclusions: POM-DEX is effective in RRMM, regardless of the latest exposure to IMiDs, PIs, and mAbs in the previous line of therapy. MDPI 2021-08-28 /pmc/articles/PMC8466559/ /pubmed/34577823 http://dx.doi.org/10.3390/medicina57090900 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Del Giudice, Maria Livia
Gozzetti, Alessandro
Antonioli, Elisabetta
Orciuolo, Enrico
Ghio, Francesco
Ciofini, Sara
Candi, Veronica
Fontanelli, Giulia
Attucci, Irene
Formica, Giuseppe
Bocchia, Monica
Galimberti, Sara
Petrini, Mario
Buda, Gabriele
Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
title Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
title_full Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
title_fullStr Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
title_full_unstemmed Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
title_short Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study
title_sort real-life experience with pomalidomide plus low-dose dexamethasone in patients with relapsed and refractory multiple myeloma: a retrospective and prospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466559/
https://www.ncbi.nlm.nih.gov/pubmed/34577823
http://dx.doi.org/10.3390/medicina57090900
work_keys_str_mv AT delgiudicemarialivia reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy
AT gozzettialessandro reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy
AT antoniolielisabetta reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy
AT orciuoloenrico reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy
AT ghiofrancesco reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy
AT ciofinisara reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy
AT candiveronica reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy
AT fontanelligiulia reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy
AT attucciirene reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy
AT formicagiuseppe reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy
AT bocchiamonica reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy
AT galimbertisara reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy
AT petrinimario reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy
AT budagabriele reallifeexperiencewithpomalidomidepluslowdosedexamethasoneinpatientswithrelapsedandrefractorymultiplemyelomaaretrospectiveandprospectivestudy